Technology Forecast for Injectables - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Technology Forecast for Injectables
A Conversation with Greystone Associates' George Perros. This article contains bonus online-exclusive material.


Pharmaceutical Technology


This article is part of PharmTech's supplement "Injectable Drug Delivery."

The rise in novel biopharmaceuticals has injected new life into the injectable delivery market. The demand for injectable technologies is growing, says George Perros, managing director for Greystone Associates, a technology consultancy based in New Hampshire, which in September 2009 published an analysis on Drug Delivery for Self-Adminstration: Devices, Drugs, Product Strategies and Forecasts. The following interview with Perros describes this evolving market and recent innovations.

PharmTech» What is your overall assessment of the future for injectables?


Table I: Global historical volume and forecast for prefilled syringes (Greystone Associates).
»Perros: The advent of protein and peptide drugs has spurred the development of new delivery devices. Newer more fragile drug substances present a delivery challenge. Nevertheless, we see not so much a revolution in injectable devices, as an evolution, as these devices become increasingly more sophisticated, cost-effective, and safe.

PharmTech» What are the main drivers of this evolution?


Table II: Current and forecast global market share for pen injector segments (Greystone Associates).
»Perros: Typically, when these biological drugs are first released onto the market, they are administered by infusion by professional healthcare providers in a healthcare facility or an outpatient setting. This is an expensive way to administer drugs, but it allows these drugs to be used in a controlled setting until enough data are available to establish a safety profile for the drug that can be used to determine whether it should be approved in a form for self-administration.

The challenge that keeps driving device evolution focuses on how to get these drugs into the hands of the patients for self-administration in a way that is safe, reliable, and economical. For drug products designed for self-injection, this means injection devices that are prefilled (also referred to as combination products).

Another issue for biological drug developers is the fragile nature of the drugs themselves, which necessitates they be transported and stored at low temperature—the so-called 'cold chain'—which adds to the cost of distribution. To avoid the problem of temperature-dependent stability, proteins and peptides are often processed and packaged in dry or powder form. These lyophilized drugs must be reconstituted prior to injection. Special injection devices have been developed that contain two chambers, one with the lyophilized active ingredient, and the second for the formulation liquid or diluent. Upon activation, the powder and liquid are allowed to mix in the correct proportions, before being injected.

The ability of patients to self-medicate reduces the economic and resource pressure of having a healthcare professional administer the drug to the patient. So the technology challenge is to design a delivery device that ensures that the drug is preserved properly, reconstituted properly if necessary, and administered at the right dose by a person who may have little or no experience with injectable devices.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here